Browsing by Author "Özcan Ö."

Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    Relationship between postural control and hand function in the subjects aged 65 years and over
    (Turkish Physical Therapy Association, 2018) Söke F.; Kul Karaali H.; Ilgin D.; Yüksel E.; Özcan Ö.; Arslan T.
    Purpose: This study was aimed to investigate the relationship between postural control and hand function in the elderly. Methods: One hundred-five elderly individuals that are 65 years old or over and living in a nursing home were included in the study. Postural control status (Berg Balance Scale) and hand function (manual dexterity: Nine Hole Peg Test, hand grip strength: handheld dynamometer, pinch grip strength: pinchmeter) of elderly individuals were evaluated. Results: The mean age of the subjects was 76.59±6.92 years, and there were 25 females (23.8%) and 80 males (76.2%). There was a statistically significant correlation between postural control and manual dexterity (dominant hand: r=0.857, p=0.001 and non-dominant hand: r=0.794, p=0.001). A statistically significant correlation between postural control and hand grip strength (dominant hand: r=0.430, p=0.001 and non-dominant hand: r=0.423, p=0.001), and a statistically significant relationship was found between postural control and pinch grip strength (dominant hand: r=0.390, p=0.001 and non-dominant hand: r=0.305, p=0.002). Conclusion: Our study showed that there was a significant relationship between postural control and hand function. This suggests that postural control-enhancing exercise programs might be useful. Therefore, we thought that further study is needed to investigate the effects of postural control to protect and improve the hand function for the elderly enhancing exercise programs for the elderly on the hand function to clarify the issue. © 2018 Turkish Physical Therapy Association. All rights reserved.
  • No Thumbnail Available
    Item
    Efficacy and Safety of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia: Retrospective Analysis of Real-Life Data; [Kronik Lenfositik Lösemili Hastalarda İbrutinib Tedavisinin Etkililiği ve Güvenilirliği: Gerçek Hayat Verilerinin Retrospektif Analizi]
    (Turkish Society of Hematology, 2021) Tombak A.; Tanrıkulu F.P.; Durusoy S.S.; Dinçyürek H.D.; Kaya E.; Ümit E.G.; Yavaşoğlu İ.; Mehtap Ö.; Deveci B.; Özcan M.A.; Terzi H.; Okay M.; Sayınalp N.; Yılmaz M.; Okan V.; Kızıklı A.; Özcan Ö.; Çetin G.; Demircioğlu S.; Aydoğdu İ.; Saydam G.; Davulcu E.A.; İlhan G.; Uçar M.A.; Özet G.; Akpınar S.; Turgut B.; Berber İ.; Kurtoğlu E.; Sönmez M.; Batur D.S.; Yıldırım R.; Özkocamaz V.; Güneş A.K.; Sahip B.; Ertop Ş.; Akay O.M.; Baştürk A.; Doğu M.H.; Akdeniz A.; Ünal A.; Seyhanlı A.; Gürkan E.; Çekdemir D.; Ferhanoğlu B.
    Objective: This study aimed to retrospectively evaluate the efficacy, safety, and survival outcome of single-agent ibrutinib therapy in chronic lymphocytic leukemia patients. Materials and Methods: A total of 136 patients (mean age ± standard deviation: 64.6±10.3 years, 66.9% males) who had received at least one dose of ibrutinib were included in this retrospective multicenter, noninterventional hospital-registry study conducted at 33 centers across Turkey. Data on patient demographics, baseline characteristics, laboratory findings, and leukemia-cell cytogenetics were retrieved. Treatment response, survival outcome including overall survival (OS) and progression-free survival (PFS), and safety data were analyzed. Results: Overall, 36.7% of patients were categorized as Eastern Cooperative Oncology Group (ECOG) class 2-3, while 44.9% were in Rai stage 4. Fluorescence in situ hybridization revealed the presence of del(17p) in 39.8% of the patients. Patients received a median of 2.0 (range: 0-7) lines of pre-ibrutinib therapy. Median duration of therapy was 8.8 months (range: 0.4-58.0 months). The 1-year PFS and OS rates were 82.2% and 84.6%, respectively, while median PFS time was 30.0 (standard error, 95% confidence interval: 5.1, 20.0-40.0) months and median OS time was 37.9 (3.2, 31.5-44.2) months. Treatment response (complete or partial response), PFS time, and OS time were better with 0-2 lines versus 3-7 lines of prior therapy (p<0.001, p=0.001, and p<0.001, respectively), with ECOG class 0-1 versus class 2-3 (p=0.006, p=0.011, and p=0.001, respectively), and with Rai stage 0-2 versus 3-4 (p=0.002, p=0.001, and p=0.002, respectively). No significant difference was noted in treatment response rates or survival outcome with respect to the presence of comorbidity, bulky disease, or del(17p). While 176 adverse events (AEs) were reported in 74 (54.4%) patients, 46 of those 176 AEs were grade 3-4, including pneumonia (n=12), neutropenia (n=11), anemia (n=5), thrombocytopenia (n=5), and fever (n=5). Conclusion: This real-life analysis confirms the favorable efficacy and safety profile of long-term ibrutinib treatment while emphasizing the potential adverse impacts of poorer ECOG performance status, heavy treatment prior to ibrutinib, and advanced Rai stage on patient compliance, treatment response, and survival outcomes. © 2021 by Turkish Society of Hematology Turkish Journal of Hematology, Published by Galenos Publishing House.
  • No Thumbnail Available
    Item
    Effect of Impairment on the Prevalence and Comorbidities of Attention Deficit Hyperactivity Disorder in a National Survey: Nation-Wide Prevalence and Comorbidities of ADHD
    (SAGE Publications Inc., 2022) Ercan E.S.; Unsel-Bolat G.; Tufan A.E.; Karakoc Demirkaya S.; Bilac O.; Celik G.; Kılıç B.G.; Akyol Ardic U.; Yalin Sapmaz S.; Aksu H.; Yolga Tahiroglu A.; Karacetin G.; Tural U.; Aktepe E.; Rodopman Arman A.; Başgül S.; Coşkun M.; Dursun O.B.; Durukan İ.; Perdahli Fiş N.; Gençoğlan S.; Gökçen C.; Sarı Gokten E.; Görker I.; Görmez V.; Yıldız Gündoğdu Ö.; Hesapçioğlu S.T.; Kandemir H.; Mutluer T.; Nasiroğlu S.; Özcan Ö.; Şahin N.; Toros F.; Perçinel Yazici İ.; Yazici K.U.; Yulaf Y.; Yüksel T.; Bilgic A.; Altun H.; Akdemir D.; Mazlum B.; Çakın Memik N.; Foto Özdemir D.; Üneri Ö.; Ünal F.
    Objective: This study aimed to determine the prevalence and comorbidities of attention-deficit hyperactivity disorder (ADHD) by evaluating a large-scale nation-wide sample of children. Method: The inclusion criterion was being enrolled as a 2nd, 3rd, or 4th-grade student. A semi-structured diagnostic interview (K-SADS-PL), DSM-IV-Based Screening Scale for Disruptive Behavior Disorders, and assessment of impairment (by both parents and teachers) were applied to 5,842 participants. Results: The prevalence of ADHD was 19.5% without impairment and 12.4% with impairment. Both ADHD with and without impairment groups had similar psychiatric comorbidity rates except for oppositional defiant disorder (ODD) and conduct disorder (CD) diagnoses. Impairment in the ADHD group resulted in significantly higher ODD and CD diagnoses. Conclusion: Even when impairment is not described, other psychiatric disorders accompany the diagnosis of ADHD and may cause impairment in the future. Impairment in the diagnosis of ADHD significantly increases the likelihood of ODD and CD. © ©The Author(s) 2021.